Mary Greeley Cancer Case Conference
Target Audience
Limited to Mary Greeley Medical Center-approved providers, referring physicians, and other health care providers who practice and/or refer patients for care.
Description
A multi-disciplinary clinical activity that serves to maintain, develop, or increase the knowledge, skills, professional performance, and relationships that a physician uses to provide services for patients, the public, or the profession. Participants will review the diagnostic procedures and treatment planning for patients with the following types of cancer: invasive ductal carcinoma, diffuse large b-cell lymphoma, carcinoma, liposarcoma, adenocarcinoma, and invasive well-differentiated keratinizing squamous cell carcinoma.
Facilitator(s)
Christopher Johnson, MD
Pathologist, McFarland Clinic, Ames, IA
Education
- MD: University of Iowa Hospitals and Clinics, Iowa City, IA
- Residency: University of Iowa Hospitals and Clinics, Iowa City, IA
- Fellowship: University of Iowa Hospitals and Clinics, Iowa City, IA
- Surgical Pathology
- Cytopathology
Professional Certifications
- American Board of Pathology
- Anatomic and Clinical Pathology
- Cytopathology
Disclosures
None of the MGMC CME Committee members who planned this CME activity have any financial relationships to disclose regarding the content of the selected cases. Trisha Andersen, DO, Jamie Weydert, MD, and Christopher Johnson, MD, the Cancer Case Conference facilitators, disclose they have no financial relationships with a commercial entity producing healthcare-related products and/or services.
Accreditation Statements
- DO: Des Moines University Medicine and Health Sciences (DMU) is accredited by the American Osteopathic Association to provide osteopathic continuing medical education for physicians. DMU designates this program for a maximum of 1.0 AOA Category 2-A credits and will report CME and specialty credits commensurate with the extent of the physician’s participation in this activity.
EDUCATIONAL GRANTS
No ineligible company provided financial support for this continuing education activity.
DISCLOSURE
Everyone in a position to control the content of this educational activity will disclose to the CME provider and attendees all relevant financial relationships with any commercial interest. The speaker(s) will disclose if any pharmaceuticals, medical procedures, and devices discussed are investigational or unapproved for use by the U.S. Food and Drug Administration (FDA). The activity director is responsible for determining educational content and selecting speakers.
DISCLAIMER
The information provided in this activity is for continuing education purposes only. It is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.
Available Credit
- 1.00 AOA Category 2A